Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxic...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Liu, Joyce F [verfasserIn] Barry, William T Birrer, Michael Lee, Jung-Min Buckanovich, Ronald J Fleming, Gini F Rimel, BJ Buss, Mary K Nattam, Sreenivasa Hurteau, Jean Luo, Weixiu Quy, Philippa Whalen, Christin Obermayer, Lisa Lee, Hang Winer, Eric P Kohn, Elise C Ivy, S Percy Matulonis, Ursula A

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2014

Umfang:	8

Übergeordnetes Werk:	Enthalten in: My - Citovsky, Vitaly ELSEVIER, 2019, London
Übergeordnetes Werk:	volume:15 ; year:2014 ; number:11 ; pages:1207-1214 ; extent:8

Links:	Volltext

DOI / URN:	10.1016/S1470-2045(14)70391-2

Katalog-ID:	ELV022458158

Internformat


LEADER	01000caa a22002652 4500
001	ELV022458158
003	DE-627
005	20230623163957.0
007	cr uuu---uuuuu
008	180603s2014 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/S1470-2045(14)70391-2 \|2 doi
028	5	2	\|a GBVA2014004000024.pica
035			\|a (DE-627)ELV022458158
035			\|a (ELSEVIER)S1470-2045(14)70391-2
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0		\|a 610
082	0	4	\|a 610 \|q DE-600
082	0	4	\|a 570 \|q VZ
084			\|a BIODIV \|q DE-30 \|2 fid
084			\|a 35.70 \|2 bkl
084			\|a 42.12 \|2 bkl
100	1		\|a Liu, Joyce F \|e verfasserin \|4 aut
245	1	0	\|a Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
264		1	\|c 2014
300			\|a 8
336			\|a nicht spezifiziert \|b zzz \|2 rdacontent
337			\|a nicht spezifiziert \|b z \|2 rdamedia
338			\|a nicht spezifiziert \|b zu \|2 rdacarrier
520			\|a Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial. We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer.
700	1		\|a Barry, William T \|4 oth
700	1		\|a Birrer, Michael \|4 oth
700	1		\|a Lee, Jung-Min \|4 oth
700	1		\|a Buckanovich, Ronald J \|4 oth
700	1		\|a Fleming, Gini F \|4 oth
700	1		\|a Rimel, BJ \|4 oth
700	1		\|a Buss, Mary K \|4 oth
700	1		\|a Nattam, Sreenivasa \|4 oth
700	1		\|a Hurteau, Jean \|4 oth
700	1		\|a Luo, Weixiu \|4 oth
700	1		\|a Quy, Philippa \|4 oth
700	1		\|a Whalen, Christin \|4 oth
700	1		\|a Obermayer, Lisa \|4 oth
700	1		\|a Lee, Hang \|4 oth
700	1		\|a Winer, Eric P \|4 oth
700	1		\|a Kohn, Elise C \|4 oth
700	1		\|a Ivy, S Percy \|4 oth
700	1		\|a Matulonis, Ursula A \|4 oth
773	0	8	\|i Enthalten in \|n The Lancet Publ. Group \|a Citovsky, Vitaly ELSEVIER \|t My \|d 2019 \|g London \|w (DE-627)ELV003173852
773	1	8	\|g volume:15 \|g year:2014 \|g number:11 \|g pages:1207-1214 \|g extent:8
856	4	0	\|u https://doi.org/10.1016/S1470-2045(14)70391-2 \|3 Volltext
912			\|a GBV_USEFLAG_U
912			\|a GBV_ELV
912			\|a SYSFLAG_U
912			\|a FID-BIODIV
912			\|a SSG-OLC-PHA
936	b	k	\|a 35.70 \|j Biochemie: Allgemeines \|q VZ
936	b	k	\|a 42.12 \|j Biophysik \|q VZ
951			\|a AR
952			\|d 15 \|j 2014 \|e 11 \|h 1207-1214 \|g 8
953			\|2 045F \|a 610

Indexfelder

author_variant	j f l jf jfl
matchkey_str	liujoycefbarrywilliamtbirrermichaelleeju:2014----:obntocdrnbnoaaivruoaaiaoeowmniheurnpaiusniiev
hierarchy_sort_str	2014
bklnumber	35.70 42.12
publishDate	2014
allfields	10.1016/S1470-2045(14)70391-2 doi GBVA2014004000024.pica (DE-627)ELV022458158 (ELSEVIER)S1470-2045(14)70391-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Liu, Joyce F verfasserin aut Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study 2014 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial. We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer. Barry, William T oth Birrer, Michael oth Lee, Jung-Min oth Buckanovich, Ronald J oth Fleming, Gini F oth Rimel, BJ oth Buss, Mary K oth Nattam, Sreenivasa oth Hurteau, Jean oth Luo, Weixiu oth Quy, Philippa oth Whalen, Christin oth Obermayer, Lisa oth Lee, Hang oth Winer, Eric P oth Kohn, Elise C oth Ivy, S Percy oth Matulonis, Ursula A oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:15 year:2014 number:11 pages:1207-1214 extent:8 https://doi.org/10.1016/S1470-2045(14)70391-2 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 15 2014 11 1207-1214 8 045F 610
spelling	10.1016/S1470-2045(14)70391-2 doi GBVA2014004000024.pica (DE-627)ELV022458158 (ELSEVIER)S1470-2045(14)70391-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Liu, Joyce F verfasserin aut Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study 2014 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial. We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer. Barry, William T oth Birrer, Michael oth Lee, Jung-Min oth Buckanovich, Ronald J oth Fleming, Gini F oth Rimel, BJ oth Buss, Mary K oth Nattam, Sreenivasa oth Hurteau, Jean oth Luo, Weixiu oth Quy, Philippa oth Whalen, Christin oth Obermayer, Lisa oth Lee, Hang oth Winer, Eric P oth Kohn, Elise C oth Ivy, S Percy oth Matulonis, Ursula A oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:15 year:2014 number:11 pages:1207-1214 extent:8 https://doi.org/10.1016/S1470-2045(14)70391-2 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 15 2014 11 1207-1214 8 045F 610
allfields_unstemmed	10.1016/S1470-2045(14)70391-2 doi GBVA2014004000024.pica (DE-627)ELV022458158 (ELSEVIER)S1470-2045(14)70391-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Liu, Joyce F verfasserin aut Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study 2014 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial. We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer. Barry, William T oth Birrer, Michael oth Lee, Jung-Min oth Buckanovich, Ronald J oth Fleming, Gini F oth Rimel, BJ oth Buss, Mary K oth Nattam, Sreenivasa oth Hurteau, Jean oth Luo, Weixiu oth Quy, Philippa oth Whalen, Christin oth Obermayer, Lisa oth Lee, Hang oth Winer, Eric P oth Kohn, Elise C oth Ivy, S Percy oth Matulonis, Ursula A oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:15 year:2014 number:11 pages:1207-1214 extent:8 https://doi.org/10.1016/S1470-2045(14)70391-2 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 15 2014 11 1207-1214 8 045F 610
allfieldsGer	10.1016/S1470-2045(14)70391-2 doi GBVA2014004000024.pica (DE-627)ELV022458158 (ELSEVIER)S1470-2045(14)70391-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Liu, Joyce F verfasserin aut Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study 2014 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial. We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer. Barry, William T oth Birrer, Michael oth Lee, Jung-Min oth Buckanovich, Ronald J oth Fleming, Gini F oth Rimel, BJ oth Buss, Mary K oth Nattam, Sreenivasa oth Hurteau, Jean oth Luo, Weixiu oth Quy, Philippa oth Whalen, Christin oth Obermayer, Lisa oth Lee, Hang oth Winer, Eric P oth Kohn, Elise C oth Ivy, S Percy oth Matulonis, Ursula A oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:15 year:2014 number:11 pages:1207-1214 extent:8 https://doi.org/10.1016/S1470-2045(14)70391-2 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 15 2014 11 1207-1214 8 045F 610
allfieldsSound	10.1016/S1470-2045(14)70391-2 doi GBVA2014004000024.pica (DE-627)ELV022458158 (ELSEVIER)S1470-2045(14)70391-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Liu, Joyce F verfasserin aut Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study 2014 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial. We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer. Barry, William T oth Birrer, Michael oth Lee, Jung-Min oth Buckanovich, Ronald J oth Fleming, Gini F oth Rimel, BJ oth Buss, Mary K oth Nattam, Sreenivasa oth Hurteau, Jean oth Luo, Weixiu oth Quy, Philippa oth Whalen, Christin oth Obermayer, Lisa oth Lee, Hang oth Winer, Eric P oth Kohn, Elise C oth Ivy, S Percy oth Matulonis, Ursula A oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:15 year:2014 number:11 pages:1207-1214 extent:8 https://doi.org/10.1016/S1470-2045(14)70391-2 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 15 2014 11 1207-1214 8 045F 610
language	English
source	Enthalten in My London volume:15 year:2014 number:11 pages:1207-1214 extent:8
sourceStr	Enthalten in My London volume:15 year:2014 number:11 pages:1207-1214 extent:8
format_phy_str_mv	Article
bklname	Biochemie: Allgemeines Biophysik
institution	findex.gbv.de
dewey-raw	610
isfreeaccess_bool	false
container_title	My
authorswithroles_txt_mv	Liu, Joyce F @@aut@@ Barry, William T @@oth@@ Birrer, Michael @@oth@@ Lee, Jung-Min @@oth@@ Buckanovich, Ronald J @@oth@@ Fleming, Gini F @@oth@@ Rimel, BJ @@oth@@ Buss, Mary K @@oth@@ Nattam, Sreenivasa @@oth@@ Hurteau, Jean @@oth@@ Luo, Weixiu @@oth@@ Quy, Philippa @@oth@@ Whalen, Christin @@oth@@ Obermayer, Lisa @@oth@@ Lee, Hang @@oth@@ Winer, Eric P @@oth@@ Kohn, Elise C @@oth@@ Ivy, S Percy @@oth@@ Matulonis, Ursula A @@oth@@
publishDateDaySort_date	2014-01-01T00:00:00Z
hierarchy_top_id	ELV003173852
dewey-sort	3610
id	ELV022458158
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV022458158</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623163957.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1470-2045(14)70391-2</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014004000024.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV022458158</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1470-2045(14)70391-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Liu, Joyce F</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial. We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Barry, William T</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Birrer, Michael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Jung-Min</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buckanovich, Ronald J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fleming, Gini F</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rimel, BJ</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buss, Mary K</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nattam, Sreenivasa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hurteau, Jean</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Luo, Weixiu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Quy, Philippa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Whalen, Christin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Obermayer, Lisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Hang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Winer, Eric P</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kohn, Elise C</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ivy, S Percy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Matulonis, Ursula A</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">The Lancet Publ. Group</subfield><subfield code="a">Citovsky, Vitaly ELSEVIER</subfield><subfield code="t">My</subfield><subfield code="d">2019</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV003173852</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:11</subfield><subfield code="g">pages:1207-1214</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1470-2045(14)70391-2</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2014</subfield><subfield code="e">11</subfield><subfield code="h">1207-1214</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
author	Liu, Joyce F
spellingShingle	Liu, Joyce F ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12 Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
authorStr	Liu, Joyce F
ppnlink_with_tag_str_mv	@@773@@(DE-627)ELV003173852
format	electronic Article
dewey-ones	610 - Medicine & health 570 - Life sciences; biology
delete_txt_mv	keep
author_role	aut
collection	elsevier
remote_str	true
illustrated	Not Illustrated
topic_title	610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
topic	ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12
topic_unstemmed	ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12
topic_browse	ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	zu
author2_variant	w t b wt wtb m b mb j m l jml r j b rj rjb g f f gf gff b r br m k b mk mkb s n sn j h jh w l wl p q pq c w cw l o lo h l hl e p w ep epw e c k ec eck s p i sp spi u a m ua uam
hierarchy_parent_title	My
hierarchy_parent_id	ELV003173852
dewey-tens	610 - Medicine & health 570 - Life sciences; biology
hierarchy_top_title	My
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)ELV003173852
title	Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
ctrlnum	(DE-627)ELV022458158 (ELSEVIER)S1470-2045(14)70391-2
title_full	Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
author_sort	Liu, Joyce F
journal	My
journalStr	My
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology 500 - Science
recordtype	marc
publishDateSort	2014
contenttype_str_mv	zzz
container_start_page	1207
author_browse	Liu, Joyce F
container_volume	15
physical	8
class	610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl
format_se	Elektronische Aufsätze
author-letter	Liu, Joyce F
doi_str_mv	10.1016/S1470-2045(14)70391-2
dewey-full	610 570
title_sort	combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
title_auth	Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
abstract	Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial. We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer.
abstractGer	Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial. We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer.
abstract_unstemmed	Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial. We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer.
collection_details	GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA
container_issue	11
title_short	Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
url	https://doi.org/10.1016/S1470-2045(14)70391-2
remote_bool	true
author2	Barry, William T Birrer, Michael Lee, Jung-Min Buckanovich, Ronald J Fleming, Gini F Rimel, BJ Buss, Mary K Nattam, Sreenivasa Hurteau, Jean Luo, Weixiu Quy, Philippa Whalen, Christin Obermayer, Lisa Lee, Hang Winer, Eric P Kohn, Elise C Ivy, S Percy Matulonis, Ursula A
author2Str	Barry, William T Birrer, Michael Lee, Jung-Min Buckanovich, Ronald J Fleming, Gini F Rimel, BJ Buss, Mary K Nattam, Sreenivasa Hurteau, Jean Luo, Weixiu Quy, Philippa Whalen, Christin Obermayer, Lisa Lee, Hang Winer, Eric P Kohn, Elise C Ivy, S Percy Matulonis, Ursula A
ppnlink	ELV003173852
mediatype_str_mv	z
isOA_txt	false
hochschulschrift_bool	false
author2_role	oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth
doi_str	10.1016/S1470-2045(14)70391-2
up_date	2024-07-06T22:02:22.136Z
_version_	1803868797284646912
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV022458158</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623163957.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1470-2045(14)70391-2</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014004000024.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV022458158</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1470-2045(14)70391-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Liu, Joyce F</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial. We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Barry, William T</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Birrer, Michael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Jung-Min</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buckanovich, Ronald J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fleming, Gini F</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rimel, BJ</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buss, Mary K</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nattam, Sreenivasa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hurteau, Jean</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Luo, Weixiu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Quy, Philippa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Whalen, Christin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Obermayer, Lisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Hang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Winer, Eric P</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kohn, Elise C</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ivy, S Percy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Matulonis, Ursula A</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">The Lancet Publ. Group</subfield><subfield code="a">Citovsky, Vitaly ELSEVIER</subfield><subfield code="t">My</subfield><subfield code="d">2019</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV003173852</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:11</subfield><subfield code="g">pages:1207-1214</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1470-2045(14)70391-2</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2014</subfield><subfield code="e">11</subfield><subfield code="h">1207-1214</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
score	7.398568

Nicht das Richtige dabei?

Schreiben Sie uns!

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?